A Pilot Study Comparing the Safety and Efficacy of Everolimus With Other Medicines in Recipients of ECD/DCD Kidneys
Status:
Terminated
Trial end date:
2017-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this pilot study is to evaluate concentration-controlled everolimus with low
dose tacrolimus compared to early conversion to CNI-free regimen and MMF/MPA with standard
dose tacrolimus in de novo renal transplant recipients of ECD/DCD kidneys. Given tacrolimus
and MMF/MPA is a widely prescribed immunosuppressive regimen in the United States,
comparisons of tacrolimus and MMF/MPA regimens to investigational therapies and treatment
regimens are needed. Also, considering the fact that ECD/DCD is a fast growing fraction of
donors, evaluation of various regimens' effects on rather delicate ECD/DCD kidneys is
necessary.